Immunotherapy for cancer is a rapidly developing treatment that modifies the immune
system and enhances the antitumor immune response. B7-H3 (CD276), a member of the B7 …

Simple Summary Melanoma is a major public health issue that claims the lives of thousands
of people every year. Furthermore, the outlook for the coming years is not encouraging with …

Dendritic cell (DC)-based vaccination for cancer treatment has seen considerable
development over recent decades. However, this field is currently in a state of flux toward …

Melanoma, the most aggressive form of cutaneous malignancy arising from melanocytes, is
frequently characterized by metastasis. Despite considerable progress in melanoma …

Uveal melanoma (UM) represents the most prominent primary eye cancer in adults. With an
incidence of approximately 5 cases per million individuals annually in the United States, UM …

Melanoma is a malignant tumor of melanocytes and is often considered immunogenic
cancer. Toll-like receptor-related genes are expressed differently in most types of cancer …

MXene, as a new two‐dimensional nanomaterial, is endowed with lots of particular
properties, such as large surface area, excellent conductivity, biocompatibility …

Messenger RNA (mRNA) vaccines are promising platforms for cancer immunotherapy
because of their potential to encode for a variety of tumor antigens, high tolerability, and …

Immune checkpoint blockade (ICB) therapy is a central pillar of melanoma treatment leading
to durable response rates. Important mechanisms of action of ICB therapy include …

Immunomodulatory therapies have fueled interest in targeting microglial cells as part of the
innate immune response after infection or injury. In this context, the colony-stimulating factor …